NIH Dot Gov reports hospitalized patients with advanced COVID-19 and lung
involvement who received remdesivir recovered faster than similar patients who
received placebo, according to a preliminary data analysis from a randomized,
controlled trial involving 1063 patients, which began on February 21. The trial
(known as the Adaptive
COVID-19 Treatment Trial, or ACTT), sponsored by the National
Institute of Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health, is the first clinical trial launched in the United States
to evaluate an experimental treatment for COVID-19.
This is wonderful news! But,
less than a week ago the MSM reported: Touted by Trump, hydroxychloroquine and remdesivir fail as coronavirus
therapy in preliminary studies I immediately labeled the story as fake news, which it was. It didn't take long to
prove it. 
No comments:
Post a Comment